Anixa Biosciences
ANIX
41 hedge funds and large institutions have $17.1M invested in Anixa Biosciences in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 8 closing their positions.
71% more capital invested
Capital invested by funds: $10M → $17.1M (+$7.09M)
55% more call options, than puts
Call options by funds: $99K | Put options by funds: $64K
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0.61% more ownership
Funds ownership: 10.73% → 11.33% (+0.61%)
9% less funds holding
Funds holding: 45 → 41 (-4)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$793K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$89.6K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$85.8K |
| 4 |
Millennium Management
New York
|
+$69.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$116K |
| 2 |
CL
CPWM LLC
Seattle,
Washington
|
-$61K |
| 3 |
Charles Schwab
San Francisco,
California
|
-$46.3K |
| 4 |
VF
Virtu Financial
New York
|
-$45K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$27K |
ANIX Hedge Fund Activity: Q3 2022 in Review
41 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q3 2022, worth a combined $17.1M — up 71% from $10M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ANIX and 5 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was BlackRock, adding an estimated $793K. The largest seller was Renaissance Technologies, cutting an estimated $116K.
- 41 institutional investors held Anixa Biosciences (ANIX) as of Q3 2022, down from 45 in Q2 2022.
- Funds reported $17.1M of Anixa Biosciences stock for Q3 2022, up 71% quarter-over-quarter.
- 5 funds opened new Anixa Biosciences positions in Q3 2022 and 8 closed out, a net change of -3 holders.
- The largest Anixa Biosciences buyer in Q3 2022 was BlackRock, an estimated $793K added.
- The largest Anixa Biosciences seller in Q3 2022 was Renaissance Technologies, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2022.